Sareum Holdings Plc - Product Pipeline Review - 2016

Date: December 30, 2016
Pages: 37
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until March 31, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S17D2778389EN
Leaflet:

Download PDF Leaflet

Sareum Holdings Plc - Product Pipeline Review - 2016

SUMMARY

Global Markets Direct’s, ‘Sareum Holdings Plc - Product Pipeline Review - 2016’, provides an overview of the Sareum Holdings Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sareum Holdings Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the pipeline therapeutic landscape of Sareum Holdings Plc
  • The report provides overview of Sareum Holdings Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sareum Holdings Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sareum Holdings Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
REASONS TO BUY
  • Evaluate Sareum Holdings Plc’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sareum Holdings Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sareum Holdings Plc’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Sareum Holdings Plc Snapshot
Sareum Holdings Plc Overview
Key Facts
Sareum Holdings Plc - Research and Development Overview
Key Therapeutic Areas
Sareum Holdings Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Sareum Holdings Plc - Pipeline Products Glance
Sareum Holdings Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Sareum Holdings Plc - Drug Profiles
CCT-244747 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-020106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-20347 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SART-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sareum Holdings Plc - Pipeline Analysis
Sareum Holdings Plc - Pipeline Products by Target
Sareum Holdings Plc - Pipeline Products by Route of Administration
Sareum Holdings Plc - Pipeline Products by Molecule Type
Sareum Holdings Plc - Pipeline Products by Mechanism of Action
Sareum Holdings Plc - Dormant Projects
Sareum Holdings Plc - Company Statement
Sareum Holdings Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Sareum Holdings Plc, Key Facts
Sareum Holdings Plc - Pipeline by Indication, 2016
Sareum Holdings Plc - Pipeline by Stage of Development, 2016
Sareum Holdings Plc - Monotherapy Products in Pipeline, 2016
Sareum Holdings Plc - Out-Licensed Products in Pipeline, 2016
Sareum Holdings Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
Sareum Holdings Plc - Preclinical, 2016
Sareum Holdings Plc - Discovery, 2016
Sareum Holdings Plc - Pipeline by Target, 2016
Sareum Holdings Plc - Pipeline by Route of Administration, 2016
Sareum Holdings Plc - Pipeline by Molecule Type, 2016
Sareum Holdings Plc - Pipeline Products by Mechanism of Action, 2016
Sareum Holdings Plc - Dormant Developmental Projects,2016
Sareum Holdings Plc, Subsidiaries

LIST OF FIGURES

Sareum Holdings Plc - Pipeline by Top 10 Indication, 2016
Sareum Holdings Plc - Pipeline by Stage of Development, 2016
Sareum Holdings Plc - Monotherapy Products in Pipeline, 2016
Sareum Holdings Plc - Pipeline by Target, 2016
Sareum Holdings Plc - Pipeline by Route of Administration, 2016
Sareum Holdings Plc - Pipeline by Molecule Type, 2016
Sareum Holdings Plc - Pipeline Products by Mechanism of Action, 2016
Skip to top


Scancell Holdings Plc - Product Pipeline Review - 2015 US$ 1,275.00 Nov, 2015 · 26 pages
Epistem Holdings Plc - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 23 pages
e-Therapeutics Plc - Product Pipeline Review - 2015 US$ 1,275.00 Jul, 2015 · 34 pages
Amura Holdings Ltd. - Product Pipeline Review - 2015 US$ 1,275.00 Apr, 2015 · 22 pages
Vaxeal Holding SA - Product Pipeline Review - 2015 US$ 1,275.00 Dec, 2015 · 18 pages

Ask Your Question

Sareum Holdings Plc - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: